EU slaps a fine of euro 10.32 million on Ranbaxy Labs for delaying the entry of cheaper drugs

20 Jun 2013 Evaluate

The European antitrust regulators, on Wednesday, slapped a fine of 146 million euro on nine pharma companies, including Ranbaxy Laboratories, for blocking the market entry of cheaper generic versions of Danish company Lundbeck’s branded citalopram, a blockbuster anti-depressant. While, the European Commission fined euro 93.8 million on Danish pharmaceutical company Lundbeck, a fine of euro 10.32 million was imposed on Ranbaxy Laboratories.

The penalty follows a 2009 report by the European Commission on the pharmaceutical sector, which pointed at 'pay-for-delay' agreements between companies, leading to consumers paying as much as 20 percent more for their medicines. Pay-for-delay agreements involve brand-name firms paying generic companies not to market rival versions of their medicine. These agreements violated the EU antitrust rules that prohibit anticompetitive agreements (Article 101 of the Treaty on the Functioning of the European Union -TFEU).

Further, country’s largest pharmaceutical company, Ranbaxy now plans to appeal to the EU General Court in Luxembourg, Europe's second-highest, after being fined 10.3 million euros.

Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×